Q-omics provides the consensus-scored SOSTDC1 profile across patient tissues and cancer cell-line models. SOSTDC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SOSTDC1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SOSTDC1 RNA expression shows 15,078 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where SOSTDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOSTDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOSTDC1 survival associations across molecular data types. SOSTDC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOSTDC1 RNA expression–survival associations across cancer types. High SOSTDC1 expression shows unfavorable associations in BLCA and DLBC, but favorable associations in HNSC, KIRC, OV and KICH. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SOSTDC1 RNA expression.
This table summarizes SOSTDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SOSTDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOSTDC1 shows lower tumor expression in KIRC, KICH, LUAD, THCA, COAD and LUSC. The KIRC box plot shows higher SOSTDC1 RNA expression in normal versus tumor tissue (log2 FC = −3.878, t-test p < 0.001).
This table shows molecular features associated with SOSTDC1 in patient tissues and cancer cell lines. In patient samples, SOSTDC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SOSTDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
